Work

47P Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy

Year: 2024

Type: article

Abstract: Fibroblast Growth Factor Receptors (FGFRs) play a crucial role in various types of cancer, yet their efficacy as therapeutic targets remains uncertain due to a significant portion of patients exhibiting resistance to FGFR inhibitors. Understanding the mechanisms behind this resistance necessitates an examination of both genetic and epigenetic factors. In this study, we investigated microRNA (miRNA) expression patterns and p53 mutation status in cancer cell lines with diverse genetic backgrounds and varying sensitivity to the novel FGFR inhibitor, CPL110.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2024.103792

Authors: M.M. Skupinska, M. Walczak, A. Mikolajczyk, M. Wieczorek, D. Popiel

Institution: Celon Pharma (Poland)

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,730